

Conference Agenda

Tuesday, July 15

- 7:00 a.m. Conference Registration / Continental Breakfast
- 7:30 a.m. Introduction
- 7:45 a.m. Welcome Address
Vijaya Raj Bhatt, MBBS, MS; Nitin Jain, MD; and Matthew Lunning, DO, FACP

Acute Myeloid Leukemia (AML)

Moderators: Vijaya Raj Bhatt, MBBS, MS and Heidi D. Klepin, MD, MS

- 8:00 a.m. World Health Organization (WHO) Classification in AML and Myelodysplastic Syndrome (MDS)
Joseph D. Khoury, MD
- 8:15 a.m. Harmonizing WHO and International Consensus Classification (ICC) Classification in AML and MDS
Sanam Loghavi, MD
- 8:30 a.m. Measurable Residual Disease (MRD) in AML: What Are the Implications?
Jerald P. Radich, MD
- 8:45 a.m. Geriatric Assessment in Leukemia: Why Should You Care?
Vijaya Raj Bhatt, MBBS, MS
- 9:00 a.m. Questions and Answers

Choosing Wisely: Upfront Treatment Intensity Selection in Adults with AML

Intensive Chemotherapy in Adults

- 9:15 a.m. Yes, and I Go Beyond 7+3
Richard M. Stone, MD
- 9:30 a.m. No, I Use Lower Intensity Chemotherapy
Keith W. Pratz, MD

Intensive Chemotherapy in Younger Adults

- 9:45 a.m. Yes, I Integrate Novel Therapies with Intensive Chemotherapy
Tapan M. Kadia, MD
- 10:00 a.m. No, It is Prime Time for Upfront Lower Intensity Triplet Therapies
Eunice S. Wang, MD
- 10:15 a.m. Questions and Answers
- 10:30 a.m. Break

Debate/Discussion: Treatment Options for Relapsed or Refractory (R/R) AML

Moderators: Joann B. Sweasy, PhD and Geoffrey L. Uy, MD

- 10:50 a.m. Targeted Therapies in R/R AML
Uma Borate, MD, MBBS
- 11:05 a.m. Targeted Radiotherapies and Other Novel Therapies in R/R AML
Geoffrey L. Uy, MD
- 11:20 a.m. Immediate Allogeneic Transplant
Krishna Gundabolu, MBBS, MS
- 11:35 a.m. Questions and Answers
- 11:50 a.m. Lunch Break (On Your Own)

Interprofessional Education

Moderators: Katherine L. Byar, MSN, ANP, BC, BMTCN® and Kim Schmit-Pokorny, MSN, RN, OCN®, BMTCN®

- 1:00 p.m. Managing Platelet Refractoriness During Intensive Antileukemia Chemotherapy
Aleh (Oleg) Bobr, MD
- 1:15 p.m. Safely Using New and Targeted Therapies for Acute Myeloid Leukemia
Allison M. Graner, PharmD, BCOP and Caitlin R. Rausch, PharmD, BCOP
- 1:45 p.m. Mitigating Risks of Intensive Acute Lymphoblastic Leukemia (ALL) Therapies and Monoclonal Antibodies
Jared E. Matya, PharmD, BCOP and Shilpa Paul, PharmD, BCOP
- 2:15 p.m. Supportive Care in Older Adults with Hematological Malignancies
Kah Poh Loh, BMedSci, MBBCh, BAO, MS
- 2:30 p.m. Team Science Approach to Managing Patients with Leukemia
Katherine L. Byar, MSN, ANP, BC, BMTCN®
- 2:45 p.m. Supporting Adolescent/Young Adult (AYA) Patients Undergoing Leukemia Treatment and Transitioning Care from Pediatric to Adult Teams
Rachael L. Schmidt, DNP, FNP-C, AOCNP®
- 3:00 p.m. Questions and Answers
- 3:15 p.m. Adjourn

Welcome Reception

7:00-9:00 p.m.

Conference participants and registered accompanying guests are invited to join. Name badges required.



Conference Agenda (continued)

Wednesday, July 16

7:00 a.m. Continental Breakfast

7:45 a.m. **Oral Abstract Presentations**

Acute Lymphoblastic Leukemia (ALL)

Moderators: Ryan D. Cassaday, MD and Nitin Jain, MD

8:15 a.m. What Have We Learned from Genetics of B-ALL and T-ALL?
Charles G. Mullighan, MBBS (Hons), MSc, MD

8:30 a.m. Questions and Answers

How Do I...

8:45 a.m. How Do I Treat Adults with Newly Diagnosed Ph-Negative B-ALL?
Marlise R. Luskin, MD, MSCE

9:00 a.m. How Do I Treat Central Nervous System Disease in ALL?
Ryan D. Cassaday, MD

9:15 a.m. How Do I Use CAR-T in Adult ALL?
Lori Muffly, MD, MS

9:30 a.m. How Do I Use CAR-T in Pediatric ALL?
Stephan A. Grupp, MD, PhD

9:45 a.m. Questions and Answers

10:00 a.m. Break

Chemotherapy Options for Upfront Management of ALL

10:20 a.m. Use of Asparaginase in ALL – When and How
Wendy Stock, MD

10:35 a.m. Chemotherapy-Free Regimens for Ph-Positive ALL
Marlise R. Luskin, MD, MSCE

10:50 a.m. BCL2 and BCL-XL Inhibition in ALL – Ready for Primetime?
Nitin Jain, MD

11:05 a.m. Questions and Answers

Myeloproliferative Neoplasms (MPN)

Moderators: Laura C. Michaelis, MD and Naveen Pemmaraju, MD

11:20 a.m. How Many Janus Kinase (JAK) Inhibitors Do We Need in Myelofibrosis (MF)?
Ruben Mesa, MD, FACP

11:35 a.m. Can We Modify the Disease in MF? How?
Naveen Pemmaraju, MD

11:50 a.m. What's New in Polycythemia Vera?
Olatoyosi Odenike, MD

12:05 p.m. What's New in Essential Thrombocythaemia?
Laura C. Michaelis, MD

12:20 p.m. Questions and Answers

12:35 p.m. Lunch Break (On Your Own)

Meet the Experts

3:00 p.m. Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome (MDS)
Moderator: Vijaya Raj Bhatt, MBBS, MS
Experts: Geoffrey L. Uy, MD; Eunice S. Wang, MD; and Olatoyosi Odenike, MD

4:00 p.m. Chronic Lymphocytic Leukemia (CLL)
Moderator: Nitin Jain, MD
Experts: Julie M. Vose, MD, MBA; Susan M. O'Brien, MD; and Matthew A. Lunning, DO, FACP

5:00 p.m. Adjourn



Conference Agenda (continued)

Thursday, July 17

7:00 a.m. Continental Breakfast

Myelodysplastic Syndrome (MDS) and Clonal Hematopoiesis

Moderators: Olatoyosi Odenike, MD and Mikkael A. Sekeres, MD, MS

7:45 a.m. Molecular International Prognostic Scoring System (IPSS-M): How Does It Affect Treatment Selection?
Elli Papaemmanuil, PhD

8:00 a.m. Biology of Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Clonal Cytopenia of Undetermined Significance (CCUS)
Joseph D. Khoury, MD

8:15 a.m. Improving the Health of Patients with CHIP/CCUS
Uma Borate, MD, MBBS

8:30 a.m. Questions and Answers

8:45 a.m. Oral Abstract Presentations

9:15 a.m. Treatment of Lower Risk MDS: Erythropoiesis-Stimulating Agents (ESA) and Beyond
Jacqueline S. Garcia, MD

9:30 a.m. Moving Beyond Hypomethylating Agent in Higher Risk MDS: Lessons Learned From Prior Failures
Amer M. Zeidan, MBBS, MHS

9:45 a.m. Triplet Therapies in MDS
Mikkael A. Sekeres, MD, MS

10:00 a.m. Managing Chronic Myelomonocytic Leukemia (CMML)
Guillermo Montalbán Bravo, MD

10:15 a.m. Questions and Answers

10:30 a.m. Break

To Transplant or Not to Transplant?

Moderators: Krishna Gundabolu, MBBS, MS and Mary M. Horowitz, MD, MS

10:50 a.m. Transplanting Lower Risk MDS: Are There Any Patients Who Would Benefit?
Marcos J. de Lima, MD

11:05 a.m. Transplanting Higher Risk MDS: Should Any Patients Not Be Transplanted?
Mary M. Horowitz, MD, MS

11:20 a.m. Upfront vs. Delayed Transplant for AML in Era of Novel Treatments and Maintenance Therapy
Upfront: Vijaya Raj Bhatt, MBBS, MS
Delayed: Andrew Wei, MBBS, PhD

11:50 a.m. Questions and Answers

12:05 p.m. Lunch Break (On Your Own)

Ask the Experts

Allogeneic Stem Transplantation

Moderators: Partow Kebriaei, MD and Catherine E. Lai, MD, MPH

1:00 p.m. Supportive Care in Older Adults Undergoing Transplant
Tanya M. Wildes, MD, MSCI

1:15 p.m. Acute Lymphoblastic Leukemia (ALL) Transplant: Upfront Indications and Consolidation Transplant Post-CAR T-Cell
Partow Kebriaei, MD

1:30 p.m. Improving Outcomes of Patients with Myelofibrosis Who Need Transplant
Nicolaus M. Kröger, MD

1:45 p.m. Preventing Post-Transplant Relapses
Marcos J. de Lima, MD

2:00 p.m. Immune Reconstitution After Allogeneic Transplant
Krishna Komanduri, MD

2:15 p.m. Prevention of Chronic Graft-Versus-Host Disease
Shannon R. McCurdy, MD

2:30 p.m. Questions and Answers

2:45 p.m. Break

Meet the Experts

3:00 p.m. Acute Lymphoblastic Leukemia (ALL)c
Moderator: Marlise R. Luskin, MD, MSCE
Experts: Stephan A. Grupp, MD, PhD; Lori Muffy, MD, MS; and Nitin Jain, MD

4:00 p.m. Myeloproliferative Neoplasms (MPN)
Moderator: Naveen Pemmaraju, MD
Experts: Ruben Mesa, MD, FACP; Jacqueline S. Garcia, MD; and Laura C. Michaelis, MD

5:00 p.m. Adjourn

Conference Dinner

7:00-10:00 p.m.

Conference participants and registered accompanying guests are invited to join. Name badges required.



Conference Agenda (continued)

Friday, July 18

7:00 a.m. Continental Breakfast

Chronic Myelogenous Leukemia (CML)

Moderators: Jane F. Apperley, MBChB, MD, FRCP, FRCPath and Jorge E. Cortes, MD

7:45 a.m. Response Assessment in CML
Jerald P. Radich, MD

8:00 a.m. Tyrosine Kinase Inhibitor (TKI) in Upfront Management of CML: Is One Superior to Others?
Michael M. Haddadin, MBBS

8:15 a.m. Management of CML Not Meeting Milestones
Fadi Haddad, MD

8:30 a.m. 3rd Generation ABL1 Kinase Inhibitors – When and How to Use Them
Jorge E. Cortes, MD

8:45 a.m. Questions and Answers

9:00 a.m. Stopping Tyrosine Kinase Inhibitor in CML: When and How
Jorge E. Cortes, MD

9:15 a.m. Mitigating Toxicities Associated with TKI
Jane F. Apperley, MBChB, MD, FRCP, FRCPath

9:30 a.m. Questions and Answers

9:45 a.m. Break

Chronic Lymphocytic Leukemia (CLL)

Moderators: Matthew Lunning, DO, FACP and Julie M. Vose, MD, MBA

Optimal Upfront Treatment in CLL: A Moving Target

10:05 a.m. Younger Patients
R. Gregory Bociek, MD, MSc, FRCP(C)

10:20 a.m. Older Patients
Nitin Jain, MD

10:35 a.m. Questions and Answers

Management of Relapsed CLL

10:50 a.m. Moving CAR T-Cell Therapy to the Center: Lessons Learned in Lymphoma
Matthew Lunning, DO, FACP

11:05 a.m. Double Refractory CLL: An Emerging Clinical Challenge
Susan M. O'Brien, MD

11:20 a.m. Richter Transformation
William G. Wierda, MD, PhD

11:35 a.m. Questions and Answers

11:50 a.m. Concluding Remarks
Matthew Lunning, DO, FACP

12:00 p.m. Adjourn

Accreditation



In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

The University of Nebraska Medical Center designates this live activity for a maximum of 23.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES

The University of Nebraska Medical Center designates this activity for up to 23.75 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

PHARMACISTS


The University of Nebraska Medical Center designates this activity for 23.75 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity.

MAINTENANCE OF CERTIFICATION (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

- 23.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.
- 23.75 MOC points in the American Board of Pathology's (ABPATH) Maintenance of Certification (MOC) program.

It is the CME Provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.



Conference Faculty

Jane F. Apperley, MBChB, MD, FRCP, FRCPath

Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom

Vijaya Raj Bhatt, MBBS, MS★

Professor; Medical Director, Leukemia Program, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Aleh (Oleg) Bobr, MD

Assistant Professor; Medical Director, Blood Bank and Tissue Services; Medical Director, Quality, Compliance, and Process Improvement; Medical Director, Regional Pathology Services; Associate Director of Apheresis Service; Consultant, Coagulation Testing Services, Department of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE

R. Gregory Bociek, MD, MSc, FRCP(C)

Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Uma Borate, MD, MBBS

Associate Professor, Division of Hematology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Katherine L. Byar, MSN, ANP, BC, BMTCN®

Nurse Practitioner, Nebraska Medicine, Omaha, NE

Ryan D. Cassaday, MD

Associate Professor, Division of Hematology and Oncology, University of Washington School of Medicine; Associate Professor, Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA

Jorge E. Cortes, MD

Director, Georgia Cancer Center; Professor, Department of Medicine; Cecil F. Whitaker Jr. GRA Eminent Scholar Chair in Cancer, Medical College of Georgia, Augusta University, Augusta, GA

Marcos J. de Lima, MD

Professor, Division of Hematology; Director of the Blood and Bone Marrow Transplant and Cellular Therapy Program, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Jacqueline S. Garcia, MD

Assistant Professor of Medicine, Harvard Medical School; Assistant Professor of Medicine, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

Allison M. Graner, PharmD, BCOP

Oncology Pharmacist, Nebraska Medicine, Omaha, NE

Stephan A. Grupp, MD, PhD

Yetta Deitch Novotny Endowed Chair in Pediatric Oncology; Section Chief of the Cellular Therapy and Transplant Section; Inaugural Director of the Susan S. and Stephen P. Kelly Center for Cancer Immunotherapy; Medical Director of the Cell and Gene Therapy Laboratory and Children's Hospital of Philadelphia, Philadelphia, PA

Krishna Gundabolu, MBBS, MS

Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Fadi Haddad, MD

Assistant Professor, Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Michael M. Haddadin, MBBS

Assistant Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Mary M. Horowitz, MD, MS

Robert A. Uihlein Jr. Professor of Hematologic Research; Director, Center for International Blood & Marrow Transplant Research; Associate Director, Cancer, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI

Nitin Jain, MD★

Professor of Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Tapan M. Kadia, MD

Professor of Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Partow Kebriaei, MD

Professor, Division of Cancer Medicine, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX

Joseph D. Khoury, MD

Stokes-Shackelford Professor and Chair, Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, NE

Heidi D. Klepin, MD, MS

Professor, Department of Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC

Krishna Komanduri, MD

Julius R. Krevans, MD Distinguished Professorship in Internal Medicine; Professor and Chief, Division of Hematology and Oncology, Department of Medicine; Physician-in-Chief, Helen Diller Family Comprehensive Cancer Center; Clinical Director, Living Therapeutics Initiative, University of California San Francisco, San Francisco, CA

Marina Konopleva, MD, PhD★

Director, Leukemia Program; Co-Director, Blood Cancer Institute, Montefiore Einstein Comprehensive Cancer Center; Professor, Oncology and Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY

Nicolaus M. Kröger, MD

Professor of Medicine; Medical Director, Department of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany

Catherine E. Lai, MD, MPH

Associate Professor of Clinical Medicine; Physician Leader, Leukemia Clinical Research Unit, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Sanam Loghavi, MD

Assistant Professor, Division of Pathology/Lab Medicine, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Kah Poh Loh, BMedSci, MBBCh, BAO, MS

Assistant Professor, Division of Hematology and Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, NY

Matthew Lunning, DO, FACP★

Assistant Vice Chancellor of Clinical Research; Associate Vice Chair of Research; Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

★ Conference Director



Conference Faculty (continued)

Marlise R. Luskin, MD, MSCE

Assistant Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Jared E. Matya, PharmD, BCOP

Clinical Pharmacist Practitioner, Blood and Marrow Transplant/Cellular Therapy, Nebraska Medicine, Omaha, NE

Shannon R. McCurdy, MD

Assistant Professor of Medicine, Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Ruben Mesa, MD, FACP

President and Executive Director, Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center; Vice Dean for Cancer Programs and Professor of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC

Laura C. Michaelis, MD

Professor of Medicine, Division of Hematology-Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

Guillermo Montalbán Bravo, MD

Assistant Professor, Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Lori Muffy, MD, MS

Associate Professor of Medicine, Blood and Marrow Transplantation & Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, CA

Charles G. Mullighan, MBBS (Hons), MSc, MD

Member, St. Jude Faculty; Deputy Director, Comprehensive Cancer Center; Co-Leader, Hematological Malignancies Program; Medical Director, St. Jude Biorepository; William E. Evans Endowed Chair, Department of Pathology, St. Jude Graduate School of Biomedical Sciences, St. Jude Children's Research Hospital Comprehensive Cancer Center, Memphis, TN

Susan M. O'Brien, MD

Associate Director for Clinical Science, Chao Family Comprehensive Cancer Center; Medical Director, Sue & Ralph Stern Center for Clinical Trials & Research; Professor, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, Irvine, CA

Olatoyosi Odenike, MD

Professor of Medicine; Director, Leukemia Program; Division of Hematology/Oncology, Department of Medicine, University of Chicago Medicine, Chicago, IL

Elli Papaemmanuil, PhD

Associate Attending, Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY

Shilpa Paul, PharmD, BCOP

Clinical Pharmacy Specialist, The University of Texas MD Anderson Cancer Center, Houston, TX

Naveen Pemmaraju, MD

Professor, Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Keith W. Pratz, MD

Associate Professor of Medicine; Section Chief, Leukemia; Director, Leukemia Program, Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Jerald P. Radich, MD

Professor, Translational Science & Therapeutics Division; Kurt Enslein Endowed Chair; Professor, Division of Hematology and Oncology, Fred Hutch Cancer Center, University of Washington School of Medicine, Seattle, WA

Caitlin R. Rausch, PharmD, BCOP

Clinical Pharmacy Specialist, The University of Texas MD Anderson Cancer Center, Houston, TX

Rachael L. Schmidt, DNP, FNP-C, AOCNP®

Program Director, Survivorship and Cancer Risk and Prevention; Assistant Director, Health Promotion and Screening, Office of Community Outreach and Engagement Health Promotion Unit, The Fred & Pamela Buffett Cancer Center, Nebraska Medicine, Omaha, NE

Kim Schmit-Pokorny, MSN, RN, OCN®, BMTCN®

Director BMT, CAR T, Cellular Therapy and Gene Therapy Program, Nebraska Medicine, Omaha, NE

Mikael A. Sekeres, MD, MS

Professor of Medicine and Chief, Division of Hematology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami Health System, Miami, FL

Wendy Stock, MD

Anjali Seth Nayak Professor of Medicine, Division of Biological Sciences, Department of Medicine, University of Chicago, Chicago, IL

Richard M. Stone, MD

Director of the Adult Acute Leukemia Program, Dana-Farber Cancer Institute, Boston, MA

Joann B. Sweasy, PhD

Director, Fred & Pamela Buffett Cancer Center; Director, Eppley Institute for Research in Cancer and Allied Diseases; Professor, Eppley Institute, University of Nebraska Medical Center, Omaha, NE

Geoffrey L. Uy, MD

Professor, Division of Oncology, John T. Milliken Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO

Julie M. Vose, MD, MBA

Division Chief and George and Peggy Payne Distinguished Chair of Oncology, Division of Hematology and Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Eunice S. Wang, MD

Chief of the Leukemia Service, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Andrew Wei, MBBS, PhD

Professor; Adjunct Professor (Research), Australian Centre for Blood Diseases, Monash University, Victoria, Australia

William G. Wierda, MD, PhD

Professor of Medicine; Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr. Elihu Estey; Section Chief, Chronic Lymphocytic Leukemia; Center Medical Director; Executive Medical Director, Inpatient Medical Services; Deputy Department Chair, Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Tanya M. Wildes, MD, MSCI

Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Amer M. Zeidan, MBBS, MHS

Associate Professor, Section of Hematology, Department of Internal Medicine, Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT

